Jon Seale, CEO of Cardiac Solutions, said, “We are extremely proud to receive this award which highlights the strength of our partnership, the life-saving value that AED Sentinel brings to our customers, and the promising growth opportunities we foresee in the future. We eagerly look forward to continuing our successful collaboration.”
About Cardiac Solutions
Cardiac Solutions, a renowned provider of public access defibrillator programs, is dedicated to promoting the widespread use of defibrillation therapy to save lives during sudden cardiac arrest incidents in unconventional healthcare settings. With a holistic approach, Cardiac Solutions offers a wide range of AED program solutions, encompassing planning, design, implementation, administration, medical oversight, training, and management, all conveniently accessible through a single point of contact. For further information, please visit www.cardiac-solutions.net.
About Readiness Systems
Readiness Systems is the foremost authority in AED program readiness and compliance nationwide. The company’s comprehensive AED inspection system ensures that AEDs are always prepared, while its AED program policies equip organizations to handle sudden cardiac arrest emergencies and mitigate legal risks. Additionally, Readiness Systems’ regulatory compliance services assist organizations in understanding and adhering to AED law requirements. Readiness Systems also provides a variety of AED program compliance tools, such as the AED Program Best Practices Guide, national AED program design guidelines, and the AED Law Center.
Professional’s expansion and growth strategy continues with new state-of-the-art clinic in Brooklyn.
MELVILLE, N.Y., Jan. 3, 2024 /PRNewswire-PRWeb/ — Professional Physical Therapy, a leading provider of outpatient physical therapy and rehabilitation services throughout New York, New Jersey, Connecticut, Massachusetts, and New Hampshire, announces the opening of a new state-of-the-art clinic in the heart of Dyker Heights, NY. This marks their third clinic opening in Brooklyn and their 34th clinic in New York City’s 5 boroughs.
The new clinic is located at 7424 13th Avenue at the corner of 13th Avenue and Bay Ridge Parkway, is just steps away from the famous Christmas lights. It was opened under Professional’s strategic partnership program that provides a unique affiliation solution to clinicians and leaders who are vested in ownership and operations.
The newest Physical Therapist Partner, Nicholas Garyfallos, MSPT is excited to open the new space in Dyker Heights and adds, “I decided to partner with Professional Physical Therapy because their commitment to providing world class patient care has made them the leaders in our profession. I am excited to finally bring this high level of patient care and satisfaction to the community I have been a part of since 1979.”
The clinic will be led by Lisa Picone, PT, DPT, LSVT, Clinical Director and says, “Professional Physical Therapy puts a great emphasis on education, patient satisfaction and care, while providing a great working environment. As Clinical Director, I am excited to bring what I have learned to serve the Dyker Heights community.”
Services at Professional Physical Therapy in the Dyker Heights clinic include:
Physical Therapy – Our physical therapists treat medical conditions that limit functional mobility and help develop a customized treatment plan to improve the ability to move, reduce pain, restore function, and prevent disability.
Orthopedic Manual Therapy – Our orthopedic clinical specialists have advanced knowledge and rigorous training in orthopedic PT, the treatment of pain related to bones, joints, and muscles.
Lee Silverman Voice Technique (LSVT) – Our certified LSVT therapist is highly trained in this technique, designed to improve motor function and teach people with Parkinson’s Disease to move more normally.
Vestibular Therapy – We have specialists with extensive experience in treating your vestibular system that includes conditions like vertigo, imbalance, and vision disturbances.
Sports Therapy – We have sports specialists with extensive training and experience to help athletes gain strength and mobility for optimal performance and return to their sport.
Post Operative Therapy – We have therapists with advanced training in post-surgical rehabilitation designed to return patients to their activities as quickly and safely as possible.
Additionally, the Dyker Heights clinic:
Accepts most major insurance plans.
Offers convenient hours, including early mornings and late evenings.
Does not require a physician referral or prescription to start treatment.
Schedules each initial evaluation quickly, sometime the same or next day.
Provides ongoing patient education on diagnosis, treatment plans and prescribed home-exercise programs.
Professional Physical Therapy currently operates widely across five of the Northeast states. For more information and a list of all Professional Physical Therapy locations and services, please visit http://www.professionalpt.com
About Professional Physical Therapy Professional Physical Therapy was founded in 1999 and is an industry leader, providing private outpatient physical and hand therapy services throughout the Northeast. Our clinical team is comprised of multi-specialty Physical, Hand and Occupational Therapists who can treat a wide variety of orthopedic injuries and conditions with excellence. Today, Professional has grown to include over 200 facilities in New York, New Jersey, Connecticut, Massachusetts, and New Hampshire.
The U.S. laboratory testing market faces multiple challenges, including post-pandemic employee wage inflation, greater utilization management and claims denials by private payers, and persistent reimbursement pressure. Despite these challenges, the U.S. lab industry has demonstrated consistent growth.
“The adoption of new higher-priced PCR-based test panels for respiratory viruses, UTIs and STDs is helping to offset price and volume pressure on routine clinical lab tests,” according to Jondavid Klipp, President of Laboratory Economics. “Physician ordering patterns are moving from low-cost culture-based microbiology tests to higher-cost more-accurate PCR tests leading to 30+% annual growth in this market.”
The report includes:
More than 100 charts and graphs
U.S. lab market size and growth rates for 2012-2025
Estimates for market subsets like hospital-based labs, independent labs, and physician-office-based labs
In-depth analysis of the PCR-based testing market size, growth rate, and highest-volume laboratories
Top 50 hospital outreach labs by Medicare CLFS and PFS payments
Detailed reimbursement rate information from Medicare CLFS, Aetna, Cigna, UnitedHealthcare, etc.
Comprehensive lab M&A valuation metrics by revenue and EBITDA
Results from Laboratory Economics Clinical Lab Trends Surveys from 2014 through 2023
The biggest challenges and opportunities for labs
Laboratory companies highlighted include:
ACL Laboratories
ARUP Laboratories
Cleveland Clinic Laboratories
Exact Sciences
Fulgent Genetics
Labcorp
Mayo Clinic Laboratories
Myriad Genetics
NeoGenomics
Northwell Health Labs
OPKO/BioReference Labs
PathAI/Poplar Healthcare
PathGroup
Quest Diagnostics
Sonic Healthcare
Sonora Quest Laboratories
The U.S. Clinical Laboratory Industry: Forecast & Trends 2023-2025 is published by Laboratory Economics (www.laboratoryeconomics.com), an independent market research firm focused exclusively on the business of pathology and laboratory medicine. Report author Jondavid Klipp has been covering key business trends affecting clinical lab testing and anatomic pathology services for more than 25 years.
Researchers conducting clinical trials for rare diseases typically face two types of recruitment issues. The first one pertains to logistics and administration. Because about half of rare disease patients are children, getting them enrolled requires significant effort and collaboration with parents and caregivers. In addition to granting consent for a potentially life-changing treatment with uncertain outcomes, adults may need to take time off work, travel to clinical sites, or even relocate altogether. As patients are not assured of experiencing an improvement in their condition, they and their families may not always perceive participation in clinical trials as worth the effort.
The second recruitment problem pertains to ensuring ethnic diversity and inclusivity within the patient pool, as different groups can exhibit different reactions to the same treatment. Inclusive clinical trials are therefore most promising at generating universal, broadly applicable findings. However, industry sponsored clinical trials for rare diseases in the US fall short from meeting this standard—despite the country’s multiethnic composition. Caucasian males are currently overrepresented in rare disease patient pools, as women and ethnic minorities often encounter biases and barriers when enrolling in clinical trials at investigator sites.
“Logistics and the lack of ethnic representation are the main factors driving patient recruitment roadblocks in rare disease clinical trials,” says Dr. Rajasimha. “Biopharmaceutical companies and clinical trial investigators must get creative in enrolling and engaging participants in the context of these obstacles. They need to look beyond the US and EU for investigator sites for enrolling diverse patients.”
The promise of patient advocacy groups Patient advocacy groups (PAGs) have been traditionally called upon by clinical investigators to assist in the recruitment for rare disease clinical trials.
PAGs can facilitate connections between both parties, enabling researchers to access a broader patient pool. On the patients’ side, these groups, often comprising individuals with firsthand experiences, can help patients understand the importance of participating in clinical trials and contributing to the advancement of medical research. For instance, PAGs can organize community events and workshops, creating environments where patients feel comfortable discussing and considering clinical trial participation.
Beyond acting as intermediaries between researchers and patients, PAGs possess a distinct advantage over the former in the recruitment of clinical trial participants. PAGs excel in providing emotional support and guidance to patients, helping them cope with their disorder with a level of empathy that researchers cannot replicate. Such support can prove invaluable in assisting patients through periods of hardship, such as the phases of a clinical study. A PAG may be the difference between a participant continuing with a study or dropping out of it.
Finally, PAGs may include healthcare professionals and other specialists among their members. This collective expertise positions these groups to actively participate in the design and implementation of clinical trials, leading to more patient-friendly protocols. For example, PAGs can devise strategies to minimize clinic visits, improve communication channels between researchers and participants, and implement culturally sensitive procedures. By enhancing the appeal of clinical trials from a patient’s standpoint, PAGs provide yet another avenue for contributing to patient recruitment and retention.
According to a study conducted in genes research, 91% of PAGs surveyed have assisted in participant recruitment, and 56% contributed to study design.4
Three modern strategies to maximize engagement with patient advocacy groups While the idea of leveraging PAGs to bolster patient recruitment efforts is well understood, making the most out of this collaboration is more complicated. Cooperation between researchers and PAGs is commonplace, but the results have not always been satisfactory. Research indicates that only 68% of surveyed PAGs had a positive experience working with researchers during clinical trials; 12% regretted their experience altogether.5
“It is not uncommon for PAGs to distrust biopharmaceutical companies,” says Rajasimha. “The former’s prioritization of patient well-being and the latter’s focus on medical advancement can result in fundamentally divergent interests.”
Given that collaboration between these entities is necessary but challenging, researchers and the companies they work for should explore new approaches to foster trust with PAGs. Creative and attuned to emerging technological trends, these strategies should empower researchers to present their best selves when engaging with PAGs in the foreseeable future.
● Set up clinical trial sites abroad: Including investigator sites in multiple countries with known prevalence of the rare disease is one of the best ways to boost diversity of patients in a clinical trial but will require collaboration with international PAGs. Such trials not only have to be compliant with local regulations and can be potentially expensive, but they directly benefit more patients and help sponsor achieve their DEIA goals to satisfy regulatory expectations.
However, organizing clinical research in other countries is more than just showing commitment to foreign rare disease patients and their advocacy groups. By having access to ethnically diverse patient pools, multinational studies address the homogeneity issue prevalent within clinical trial cohorts in the US and/or EU.
A particularly suitable country for hosting clinical trial sites for US biopharmaceutical firms is India. Despite the country representing one-third of global rare disease cases and the Indian diaspora constituting a sizable proportion of the American population, participants of Indian origin accounted for merely 1% in US-based rare disease clinical trials.6
● Integrate new, AI-powered clinical management tools: Even when researchers and PAGs are committed to working together, engagement and communication can be problematic when both parties are collaborating from disparate geographical locations. Routine activities, including coordinating and hosting in-person meetings and events, documentation, and record-keeping, and ensuring PAGs are well-versed with the specifics of the clinical trial process, suddenly become veritable setbacks.
Modern clinical management tools, inspired by the popularity of remote patient access, can align researchers and PAGs more closely. Features such as omni-channel communication, eDocumentation, automated workflows, and process modularization effectively address most operational barriers while elevating the scalability of clinical trials to unprecedented levels.
A notable clinical management platform tailored for modern clinical trials, including for rare diseases, is the Jeeva eClinical SaaS system. Utilizing AI for automation, remote screening, and home-based trial participation, the software can play a crucial role in assisting researchers and PAGs with patient recruitment and engagement.
● Involve nonprofits: Nonprofits facilitate partnerships between industry and PAGs, amplifying impact and driving even more positive outcomes. Often situated at the center of the rare disease community, nonprofits comprehend the values and priorities of different PAGs and can advise researchers on approaching the latter effectively. Bringing a nonprofit onboard also adds legitimacy to the partnership, cultivating trust from both sides.
Nonprofits offer concrete resources that can aid engagement with PAGs as well. Grant programs allow PAGs to organize outreach campaigns and sustain prolonged recruitment drives for clinical trials. In the event a PAG encounters a knowledge gap hindering collaboration with investigators, a nonprofit can provide training through conferences, webinars, and workshops.
“A nonprofit organization I founded, the Indo US Organization for Rare Diseases (IndoUSrare), has a long history of bridging geographic silos and gaps between industry partners, researchers, and patient advocacy groups,” says Rajasimha, CEO. “A few months ago, we organized our inaugural Indo US Bridging RARE summit at George Mason University, where we flew in patient advocates and connected them with global experts.”
Together, these strategies should permit researchers to establish more fruitful relationships with PAGs. Conducting inclusive modern clinical trials with international sites signals dedication to the patients globally and expands the available patient pool for researchers. Adopting sophisticated clinical management tools solves important organizational and operational conundrums that arise during these unions. Serving as force multipliers, nonprofits can add considerable value to these endeavors as well.
Collaborate across borders with confidence Researchers’ struggle to recruit enough eligible patients within a limited time frame for clinical trials remains one of the greatest challenges blocking medical progress in this field. Engaging patient advocacy groups (PAGs) early on during the clinical trial process has demonstrated success in galvanizing timely patient recruitment and retention. Nonetheless, successful teamwork between researchers and PAGs is far from guaranteed—a troubling aspect given that rare diseases impact millions.
Perhaps sponsors of orphan drugs have much to gain by considering alternative frameworks of patient engagement in clinical trials. Establishing clinical trials in selected countries for the purposes of diversity and inclusion, integrating AI-powered modern clinical trial management platforms, and bringing in nonprofits as a third party are all part of winning strategies.
“For various reasons, including the political environment, the incentives for the biopharmaceutical industry to invest in rare disease research and orphan drug development are declining,” says Rajasimha. “Going forward, the quality of collaboration between industry, clinical researchers, and patient advocacy groups will play a magnified role; cross-border cooperation among all stakeholders will be essential.”
“We are excited to collaborate in the Bullpen with Dr. Rajasimha and team IndoUSrare during the 42nd annual JP Morgan Healthcare Investors Week Rare Disease event at the Golden Gate Yacht Club.” says Christiaan Engstrom, Founder of Bullpen.
About IndoUSrare: IndoUSrare is a humanitarian nonprofit 501(c)(3) tax-exempt public charity organization based in the United States. Founder and Executive Chairman Dr. Harsha Rajasimha, who lost a child to a rare disease in 2012, has been a rare disease advocate for more than 10 years. To address the unmet needs of diverse patients with rare diseases globally, the leadership team comprised of experienced professionals from research, advocacy, regulatory, and drug development seeks to build cross-border collaborations connecting stakeholders of rare diseases in low- and middle-income regions such as India, with their counterparts and clinical researchers in the United States to improve the diversity of clinical trial participants, accelerate research and development, and improve equitable access to life-saving therapies to diverse populations of rare disease patients. Visit https://indousrare.org.
References: 1. NORD. “Rare Disease Database.” NORD, rarediseases.org/rare-diseases/. Accessed 19 Dec. 2023. 2. NORD. “Rare Disease Day: Frequently Asked Questions.” NORD, rarediseases.org/wp-content/uploads/2019/01/RDD-FAQ-2019.pdf. Accessed 19 Dec. 2023. 3. Desai, Mira. “Recruitment and retention of participants in clinical studies: Critical issues and challenges.” Perspect Clin Res, ncbi.nlm.nih.gov/pmc/articles/PMC7342339/#ref7. Accessed 19 Dec. 2023. 4. Landy, David C. et al. “How disease advocacy organization participate in clinical research: a survey of genetic organizations.” Genetics in Medicine, sciencedirect.com/science/article/pii/S1098360021041629. Accessed 20 Dec. 2023. 5. Ibid. Accessed 20 Dec. 2023. 6. Chakraborty, Monoswi et al. “Rare disease patients in India are rarely involved in international orphan drug trials.” PLOS Global Public Health, journals.plos.org/globalpublichealth/article?id=10.1371/journal.pgph.0000890. Accessed 20 Dec. 2023. 7. Ibid. Accessed 20 Dec. 2023.
Media Inquiries: Karla Jo Helms JOTO PR™ 727-777-4619 jotopr.com
Media Contact
Karla Jo Helms, JOTO PR™, 727-777-4629, [email protected], jotopr.com
“We are thrilled to welcome Russell Henley to Team symplr,” said Kristin Russel, Chief Marketing Officer of symplr. “Henley’s attitude and character on and off the golf course are exemplary of everything we stand for at symplr—teamwork, determination, and results—the same traits that symplr prioritizes to provide healthcare organizations with better operations for better outcomes. I’m excited to cheer him on as one of our PGA TOUR Ambassadors.”
“I’m honored to partner with symplr as a PGA TOUR Ambassador,” said Henley. “symplr’s mission of optimizing healthcare operations so that doctors and nurses can spend more time and resources on providing the best possible patient care is something I care deeply about, as healthcare is something that affects all of us and our loved ones. I’m excited to see how our partnership continues to grow.”
symplr is offering increased engagement and collaboration with Team symplr golfers in 2024, with opportunities for employees and customers to support players at local tournaments. Team symplr was launched in January 2022.
About symplr symplr is a leader in enterprise healthcare operations software and services. For more than 30 years and with deployments in 9 of 10 U.S. hospitals, symplr has been committed to improving healthcare operations through its cloud-based solutions, driving better operations for better outcomes. Our provider data management; workforce management; compliance, quality, and safety; and contract, supplier, and spend management solutions improve the efficiency and efficacy of healthcare operations, enabling caregivers to quickly handle administrative tasks so they have more time to do what they do best: provide high-quality patient care. Learn how at symplr.
Media Contact Ashley Richardson, symplr, 617-275-6519, [email protected]
MeldRx allows apps to link to any external FHIR APIs in real time using SMART specifications. This capability allows healthcare organizations to get valuable tools into the hands of clinicians at the point of care much faster, helping to improve patient outcomes and in certain cases, potentially saving lives. MeldRx reduces EHR complexity and provides shared services for development, testing, integration, and compliance, thus streamlining the overall development and deployment process.
Other Darena Solutions’ accomplishments in 2023 include:
CONTINUED MARKET LEADERSHIP Darena’s MyMipsScore software continues to be one of the leading Merit-based Incentive Payment System (MIPS) solutions available. MyMipsScore has been a MIPS Qualified Registry for seven consecutive years, entrusted by the Centers for Medicare and Medicaid Services (CMS) with collecting MIPS data from eligible clinicians and submitting it to the federal agency.
FORGING A NEW PATH Darena forged an unprecedented partnership for SMART on FHIR and an AI-focused healthcare app certification program with the three ONC-authorized certifying bodies (ONC-ACBs), Drummond, Leidos, and SLI Compliance that would leverage Darena’s MeldRx platform.
EXPANDING IMPACT ON SPECIALTY EHRS Darena’s innovative technology and comprehensive services are now empowering an even broader spectrum of medical specialties. These include the critical fields of Behavioral Health, Neurology, Ophthalmology, Cardiology, and Urology, as well as vital areas like Oncology, Dermatology, Podiatry, Wound Care, Radiology, Substance Abuse, Physical Therapy, Urgent Care, Internal Medicine, and Hospitalist services. This expansion underscores Darena’s commitment to enhancing healthcare delivery across diverse medical fields, reinforcing Darena’s position as a valued partner in the EHR industry.
LIGHTING THE WAY Darena has one of the largest listings of FHIR APIs, according to HealthIT.gov’s Lantern dashboard. Lantern is an FHIR API monitoring system created by ONC to track and publicly provide nationwide analytics about the availability and standardization of FHIR API service base URLs (“FHIR Endpoints”) deployed by healthcare organizations.
“This past year has been exciting at Darena Solutions and has set the stage for more growth and continued success in realizing our vision of improving healthcare by facilitating app development and information sharing among providers, payers, and patients,” said Pawan Jindal, Founder and Chief Executive Officer of Darena Solutions. “Our goal in 2024 is to build on this momentum as we work together toward a healthier tomorrow.”
COME SEE DARENA AT VIVE 2024 INTEROPNOW! Darena Solutions will be featured in InteropNow! Pavilion at ViVE 2024 in the Los Angeles Convention Center from Feb. 25-28. Darena team invites like-minded partners and clients to their booth to share their ideas and be a part of the conversation about shaping the future of healthcare.
ABOUT DARENA SOLUTIONS Darena Solutions delivers an ecosystem of FHIR® enabled interoperability, regulatory compliance, and analytics solutions to EHRs, providers, and payers. In addition to MeldRx, Darena Solutions provides regulatory solutions MyMipsScore™ and BlueButtonPRO. MyMipsScore is one of the leading solutions for MIPS that, as a CMS Qualified Registry, supports all eCQMs and registry measures. BlueButtonPRO was the nation’s first 2015 Edition ONC-certified FHIR API solution and has one of the largest listings of live FHIR APIs as per the HealthIT.gov Lantern Dashboard. By creating channels for data sharing between providers, payers, and patients, Darena enables healthcare organizations to achieve interoperability compliance and derive insights for prospective decision-making, resulting in better patient outcomes. Connect with us on LinkedIn and X.
A staple of the community, U.S. Dermatology Partners Weatherford is led by Board-Certified Certified Dermatologist Dr. Dustin Wilkes and staffed by Certified Physician Assistants Kyla Crispe, McKenzie Bartlett, and Meagan Johnson,PA-C, Certified Nurse Practitioner Raylee Baber. The Weatherford office includes a full menu of services, including annual skin exams, the treatment of chronic skin conditions, including acne, psoriasis, and eczema, and the diagnosis and treatment of skin cancer.
To schedule an appointment at U.S. Dermatology Partners Weatherford, please contact the office at (817) 594-5880 or click here to request an appointment online.
About U.S. Dermatology Partners U.S. Dermatology Partners is one of the premier dermatology practices in the country, caring for nearly two million patients each year. With over 100 locations across eight states that span large metroplexes and rural, underserved communities, they provide the benefits of private, personalized levels of care paired with a network of coordinated, specialized dermatology physicians. U.S. Dermatology Partners is fervently focused on providing the highest level of compassionate and comprehensive patient-first care, making it seamless for all people to connect with dermatologists and national leaders in areas such as clinical research, psoriasis, and Mohs surgery and gain access to state-of-the-art dermatological treatments, surgical and cosmetic dermatology. To learn more, visit usdermatologypartners.com
Beginning January 1, Parsons began leading the Client Services, Sales, and Marketing teams.
Simultaneously, Logan Moser has been promoted to Director of Client Services. He has been a critical member of the team for more than seven years. He has continuously demonstrated his core strength of fostering positive client relationships.
“Both Tracy and Logan have demonstrated their commitment to our core value of excellence in their development of client relationships,” said Kris Aeschlimann, State’s chief financial officer. “I believe both will continue to serve our clients and lead our teams exceptionally well.”
The State family appreciates Beard’s dedication and commitment to our clients for so many years and is delighted to support him as he begins this lengthy transition. You can still expect to see Beard at several upcoming conferences.
State is confident this extended transition and well-deserved promotions will only strengthen the quality service clients have come to expect from State. Our team looks forward to another year of partnering together to best serve our clients and their patients.
About State
State improves the financial picture for healthcare providers by delivering increased financial results while ensuring a positive patient experience. Rooted in a tradition of ethics, integrity and innovation since 1949, State uses data analytics to drive performance and speech analytics with ongoing training to ensure patient satisfaction. A family-owned company now in its third generation of leadership, State assists healthcare organizations with services spanning the complete revenue cycle, including Pre-Service Financial Clearance, Early Out Self-Pay Resolution, Insurance Follow-Up and Bad Debt Collection. To learn more, visit: www.statecollectionservice.com.
Thought Technology’s range of products provides different levels of functionality to suit individual needs. The ProComp Infiniti®, with an 8 channel capacity, is one of the products offered. Another product is the eVu TPS®, which uses a wireless sensor to collect and analyze physiological data and can be used in combination with a companion app.
The CapnoTrainer® GO system is a hardware and software combination that offers personalized breathing education tools based on the principles of behavioral analysis. The software provides both live and recorded physiology readings, which help users identify and modify both good and bad breathing habits. Users can disengage bad habits that compromise their physical and mental competence and learn new ones that promote health and performance.
Based on live real-time feedback of breath-to-breath changes in alveolar CO 2 concentration, the GO provides for learning breathing habits that optimize respiration and its associated acid-base physiology.
Helen Mavros, Director of Sales and Marketing at Thought Technology, expressed enthusiasm for the partnership with Better Physiology and the added benefits capnometry offers. She stated, “Adding a biofeedback training component will allow users of the CapnoTrainer® GO device to monitor and train modalities beyond respiration. We are excited to introduce our customer base to the added benefits capnometry offers and to include Better Physiology as one of our partners.”
Better Physiology founder, Peter Litchfield commented, “Better Physiology looks forward to working with the world leader in biofeedback technology, Thought Technology, a team of professionals who can bring our new CapnoTrainer technology to the biofeedback community worldwide. Capnography should be a basic modality used by biofeedback and neurofeedback practitioners everywhere.”
About Better Physiology Better Physiology, Ltd. was incorporated in May of 2000. It is a privately held USAWyoming corporation owned by 52 stockholders from around the world, all of whom subscribe to the Company mission.
The Company was founded based on statistics suggesting that millions of people worldwide suffer with the profound and misunderstood symptoms and deficits of learned dysfunctional breathing habits. Unfortunately, these habits are rarely identified by practitioners, their effects mistakenly attributed to other causes, and their resolutions prescriptive in nature where focus is on symptoms rather than on causes.
About Thought Technology Ltd. Founded in 1975, Thought Technology is the world’s leading biofeedback and physiological instrument manufacturer. Its products are used as an essential part of many therapeutic treatments and clinical assessment protocols in over 85 countries and are used by tens of thousands of clinicians in thousands of medical institutions.
Always supportive of new research and development ideas, Thought Technology Ltd. has encouraged a number of special interest groups and clinicians to create cutting edge applications for its instrumentation. Thought Technology Ltd. equipment is now being used in telemedicine, web-based monitoring and biofeedback, sports training, research in human-machine interface, physiology-driven multimedia environments and virtual reality. Constantly striving to improve the quality of the products and services, TTL has obtained, and maintains, ISO 13485, and CE certification for the organization and products.
Dr. Andrus is currently a top Dentist in the endodontics specialty. “I look forward to contributing my specialized training and experience to uphold North County Endodontics’ standard of excellence in patient care.”
Dr. Andrus joins Dr. Garland and Dr. Kardosh in bringing exceptional training and specializations to North County Endodontics. Dr. Garland graduated from the University of Southern California School of Dentistry, where he earned a Doctorate of Dental Surgery (DDS). After practicing general dentistry for seven years, he went back to school to specialize in endodontics. He was accepted into the post-doctoral residency program at Loma Linda University, where he received a Certificate in Endodontics.
Dr. Garland was the first endodontist in the area to utilize GentleWave technology for more comfortable root canal treatments. North County Endodontics is dedicated to using the latest technology and techniques to provide pain-free procedures.
Dr. Kardosh received her Doctorate of Dental Surgery (DDS) from the University of Detroit Mercy and relocated to San Diego to complete her general practice residency at Naval Medical Center San Diego. After serving three years onboard USS Germantown, Dr. Kardosh transitioned into the Reserves and practiced as a general dentist in Oceanside, CA for two years before specializing in Endodontics. In 2013, she graduated from the Long Beach VA Endodontic Residency and practiced Endodontics in Phoenix, AZ, from 2013 to 2021.
North County Endodontics offers a full range of endodontic services using specialized technology such as GentleWave for your family including:
Root Canal Therapy
GentleWave Procedure
Endodontic Retreatment
Regenerative Endodontics
Cracked Teeth
Dental Trauma
Internal Teeth Whitening
With the website update and new addition to the team, North County Endodontics reiterates its commitment to being the leading provider of endodontic services in North County. They look forward to continuing to serve patients with the highest quality of care.
About North County Endodontics, LLC
North County Endodontics, LLC is located at 531 Encinitas Blvd. Suite 101, Encinitas, CA 92024. For more information or to schedule an appointment, visit https://www.northcountyendo.com or call 760-944-0048.
